Company profile
Endonovo Therapeutics, Inc.
OTC: ENDV · Healthcare · Biotechnology
PublicHQ Woodland Hills, CACIK 0001528172Reports USD
#1024 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 43GM —SS 26
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), disclosure history · ↓ workforce scale, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$18.5M
Employees
1
as of 2026-08-29
Market cap
$31.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$135.4k$135.4k2022
Net income-$18.5M-$18.5M2022
Operating income-$3.3M-$3.3M2022
Total assets$1.3M$1.3M2022
Liabilities$33.5M$33.5M2022
Equity-$32.2M-$32.2M2022
Revenue trend
FY2014 – FY2022 · USD
FY14
FY14
FY15
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2022
By product
Royalty84%
Direct Sales Medical Care Providers Gross16%
By geography
Not disclosed.
The read
What is Endonovo Therapeutics, Inc.’s revenue?
Endonovo Therapeutics, Inc. booked $135.4k in FY2022 revenue, growing 85% year over year — faster than most Healthcare companies we track, at a -13649.2% net margin.
Peers · Healthcare
Anthera Pharmaceuticals, Inc.——VivoSim Labs, Inc.——Sigyn Therapeutics, Inc.——Serina Therapeutics, Inc.41DVentriPoint Diagnostics Ltd.31DPanamera Holdings Corporation31DKey facts
CEOAlan Brian Collier
SectorHealthcare
IndustryBiotechnology
HeadquartersWoodland Hills, CA
ExchangeOTC: ENDV
Employees1
IPO date2012-11-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.